Sight Sciences to Host SAHARA 6 Month RCT Results Reception at the American Academy of Ophthalmology 2023
19 Outubro 2023 - 5:05PM
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the
“Company”), an eyecare technology company focused on developing and
commercializing innovative technology intended to transform care
and improve patients’ lives, today announced they will be hosting a
TearCare SAHARA Six Month RCT Results reception in San
Francisco, CA on Friday, November 3, 2023 from 5:00 to 7:00 pm PT.
A live and archived webcast of the event will be
available on Sight Sciences’ investor relations website
at https://investors.sightsciences.com. Please note that
Q&A will be conducted live, in-person only following the formal
presentation.
In-person attendance at the event will be
limited and require advanced registration. Please
email Hannah@gilmartinir.com by October 30, 2023 to
request an invitation.
About Sight SciencesSight
Sciences is an eyecare technology company focused on developing and
commercializing innovative solutions intended to transform care and
improve patients’ lives. Using minimally invasive or non-invasive
approaches to target the underlying causes of the world’s most
prevalent eye diseases, Sight Sciences seeks to create more
effective treatment paradigms that enhance patient care and
supplant conventional outdated approaches. The Company’s OMNI®
Surgical System is a minimally invasive glaucoma surgery (“MIGS”)
technology indicated to reduce intraocular pressure in adult
patients with primary open-angle glaucoma (“POAG”), the world’s
leading cause of irreversible blindness. The Company’s TearCare
System technology is 510(k) cleared for the application of
localized heat therapy in adult patients with evaporative dry eye
disease due to meibomian gland dysfunction (“MGD”) when used in
conjunction with manual expression of the meibomian glands,
enabling office-based clearance of gland obstructions by physicians
to address the leading cause of dry eye disease. The Company’s
SION™ Surgical Instrument is a manually operated device used in
ophthalmic surgical procedures to excise trabecular meshwork.
For more information, visit
www.sightsciences.com.
OMNI and TearCare are registered trademarks of
Sight Sciences.SION is a trademark of Sight Sciences.Restasis is a
registered trademark of Allergan, an AbbVie company.
© 2023 Sight Sciences. All rights reserved.
Media
contactpr@SightSciences.com
Investor contact:Philip TaylorGilmartin
Group415.937.5406Investor.Relations@Sightsciences.com
Sight Sciences (NASDAQ:SGHT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Sight Sciences (NASDAQ:SGHT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024